Kenvue Inc. $KVUE Shares Acquired by CIBC Asset Management Inc

CIBC Asset Management Inc raised its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 54.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 491,896 shares of the company’s stock after acquiring an additional 173,725 shares during the period. CIBC Asset Management Inc’s holdings in Kenvue were worth $8,485,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of KVUE. Cornerstone Planning Group LLC lifted its stake in Kenvue by 705.2% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock valued at $25,000 after acquiring an additional 1,361 shares during the period. Physician Wealth Advisors Inc. increased its holdings in shares of Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares in the last quarter. Elyxium Wealth LLC purchased a new position in shares of Kenvue during the 4th quarter valued at approximately $26,000. SBI Securities Co. Ltd. increased its holdings in shares of Kenvue by 82.4% during the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after purchasing an additional 1,027 shares in the last quarter. Finally, Atlantic Union Bankshares Corp increased its holdings in shares of Kenvue by 184.1% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 2,619 shares of the company’s stock valued at $43,000 after purchasing an additional 1,697 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

NYSE:KVUE opened at $17.72 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. The stock has a market capitalization of $34.01 billion, a P/E ratio of 20.84, a PEG ratio of 1.28 and a beta of 0.54. The company has a 50 day moving average price of $17.37 and a 200 day moving average price of $17.48. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $22.87.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the company posted $0.24 EPS. Equities research analysts forecast that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were paid a dividend of $0.2075 per share. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.7%. Kenvue’s dividend payout ratio is 97.65%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Citigroup cut their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Argus raised shares of Kenvue to a “hold” rating in a report on Friday, March 6th. Weiss Ratings lowered shares of Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 29th. UBS Group cut their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a report on Tuesday, April 7th. Finally, Barclays cut their target price on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $19.33.

Insider Transactions at Kenvue

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.59% of the stock is owned by company insiders.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.